Physician profile
Rebekah Laughlin
NPI 1477035756
$2,455.59
in general payments reported to CMS, 2019-2025
16 companies · $930 in 2025
The $930 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $99.87 · 2023: $752 · 2024: $674 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,355.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $427.77 | 2022-2024 | Airsupra, Fasenra |
| E.R. Squibb & Sons, L.L.C. | $264.72 | 2023-2024 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.28 | 2024-2025 | |
| Dexcom, INC. | $222.42 | 2024-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Mallinckrodt Hospital Products INC. | $178.98 | 2023-2025 | Acthar |
| Lilly USA, LLC | $133.25 | 2025 | Zepbound, Mounjaro |
| Avadel Cns Pharmaceuticals, LLC | $125.00 | 2025 | Lumryz |
| Gilead Sciences, INC. | $125.00 | 2024 | Descovy |
| Bayer Healthcare Pharmaceuticals INC. | $120.00 | 2024 | |
| Insulet Corporation | $113.08 | 2025 | Omnipod |
| Phadia US INC. | $101.77 | 2023 | Immunocap |
| Phathom Pharmaceuticals, INC. | $101.28 | 2025 | Voquezna |
| Novo Nordisk INC | $100.00 | 2025 | |
| Amgen INC. | $88.14 | 2023 | Repatha |
| Glaxosmithkline, LLC. | $88.04 | 2023 | Bexsero |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $27.86 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebekah Laughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.